Shukra Pharmaceuticals Changes Name to Shukra Medtech Limited
Shukra Pharmaceuticals Limited announced its name change to Shukra Medtech Limited, effective October 12, 2026, following approval from the Ministry of Corporate Affairs. This strategic move aligns with business restructuring and future corporate strategy. The company is updating its records with stock exchanges for a new trading symbol.
A name change can signal strategic shifts and may impact market perception and future business direction, warranting a medium impact assessment.
The announcement is a factual update regarding a name change and does not inherently carry positive or negative financial implications.
Shukra Pharmaceuticals Limited has officially changed its name to Shukra Medtech Limited. The Ministry of Corporate Affairs (MCA) has approved this change, and a fresh Certificate of Incorporation reflecting the new name was issued on October 12, 2026. This name change is part of the company's business restructuring and alignment with its future corporate strategy and technology requirements.
The company is currently completing the necessary formalities with the Stock Exchanges to update its records and transition to a new trading symbol. Shukra Medtech Limited, formerly Shukra Pharmaceuticals Limited, is based in Ahmedabad, Gujarat.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.